{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:02:37Z","timestamp":1777957357799,"version":"3.51.4"},"reference-count":21,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006356","name":"Syddansk Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Biological treatment has been a game changer in the management of moderate\u2010to\u2010severe psoriasis. In Denmark, biological treatment for psoriasis is registered in two data sources. We aimed to describe the utilization of biologics for psoriasis in Denmark using data from both data sources separately.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used data from two different nationwide Danish data sources: The healthcare registries and the clinical quality database, Dermbio. Utilization patterns were described by three different parameters: (1) distribution of drugs used in the first treatment episodes, (2) treatment cascade on a population level, and (3) drug survival using Kaplan Meier (KM) analysis and the proportion of patients covered (PPC) method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From January 1, 2011, to December 31, 2018, we found 1878 users of biologics in the healthcare registries and 2264 in Dermbio. Adalimumab, ustekinumab, and secukinumab were the most common first\u2010choice treatments throughout the study period. According to the healthcare registries, it was most common to have more than one treatment episode with the same drug. In Dermbio, most were registered to have only one observable treatment episode overall in the study period. Ustekinumab showed the longest drug survival in both databases. Drug survival was longer for all biologics in Dermbio than in the healthcare registries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Adalimumab, ustekinumab, and secukinumab were the most common first\u2010choice treatments in Denmark. Overall, ustekinumab showed the longest drug survival. We observed important differences in treatment cascades and drug survival between Dermbio and the healthcare registries, which should be considered when using these data sources to perform drug utilization studies on biologics.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.70050","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T04:25:12Z","timestamp":1730867112000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biologics Used for Psoriasis: A Drug Utilization Study Based on Two Nationwide Danish Data Sources"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8613-5892","authenticated-orcid":false,"given":"Nanna\u00a0Philbert","family":"Engel\u2010Andreasen","sequence":"first","affiliation":[{"name":"Clinical Pharmacology and Pharmacy, Department of Public Health University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8097-8708","authenticated-orcid":false,"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacy, Department of Public Health University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jensen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacy, Department of Public Health University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology Bispebjerg Hospital  Copenhagen Denmark"},{"name":"Department of Clinical Medicine Faculty of Health and Medical Sciences, University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Reilev","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacy, Department of Public Health University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051690"},{"key":"e_1_2_9_3_1","unstructured":"\u201cDansk Dermatologisk SelskabRetningslinjer for behandling af patienter med psoriasis og behov for lys eller systemisk behandling \u201daccessed October 28 2024 https:\/\/dds.nu\/wp\u2010content\/uploads\/2024\/03\/Guideline\u2010DDS\u20102.\u2010generations\u2010immunomodulatorisk\u2010behandling\u2010opdatering\u2010december\u20102023_Final\u20101.pdf."},{"key":"e_1_2_9_4_1","unstructured":"\u201cDermbio \u2013 Biologisk behandling i dansk dermatologi \u2013 sundhed.dk \u201daccessed September 13 2021 https:\/\/www.sundhed.dk\/sundhedsfaglig\/kvalitet\/kliniske\u2010kvalitetsdatabaser\/kroniske\u2010sygdomme\/dermbio\u2010biologisk\u2010behandling\u2010i\u2010dansk\u2010dermatologi\/."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13343"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555\u20103331"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v101.351"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654\u2010014\u20109930\u20103"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw213"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21595"},{"key":"e_1_2_9_12_1","unstructured":"\u201cInternational Classification of Diseases (ICD) \u201daccessed January 12 2022 https:\/\/www.who.int\/standards\/classifications\/classification\u2010of\u2010diseases."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13472"},{"key":"e_1_2_9_14_1","unstructured":"\u201cThe Anatomical Therapeutic Chemical Classification System With Defined Daily Doses (ATC\/DDD) \u201daccessed January 12 2022 https:\/\/www.who.int\/standards\/classifications\/other\u2010classifications\/the\u2010anatomical\u2010therapeutic\u2010chemical\u2010classification\u2010system\u2010with\u2010defined\u2010daily\u2010doses."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15991"},{"key":"e_1_2_9_16_1","unstructured":"\u201cMedicinr\u00e5dets l\u00e6gemiddelrekommandation vedr\u00f8rende l\u00e6gemidler til moderat til sv\u00e6r plaque psoriasis \u201daccessed October 28 2024 https:\/\/medicinraadet.dk\/anbefalinger\u2010og\u2010vejledninger\/behandlingsvejledninger\u2010og\u2010laegemiddelrekommandationer\/psoriasis\u2010og\u2010psoriasis\u2010med\u2010ledgener."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4582"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4114"},{"key":"e_1_2_9_19_1","unstructured":"\u201cLov Om Videnskabsetisk Behandling Af Sundhedsvidenskabelige Forskningsprojekter Paragraf 10.\u201d"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555\u20103278"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.625755"},{"key":"e_1_2_9_22_1","unstructured":"\u201cPsoriasis og psoriasis med ledgener \u201daccessed March 18 2021 https:\/\/medicinraadet.dk\/anbefalinger\u2010og\u2010vejledninger\/behandlingsvejledninger\/psoriasis\u2010og\u2010psoriasis\u2010med\u2010ledgener."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T03:42:37Z","timestamp":1738035757000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1002\/pds.70050"],"URL":"https:\/\/doi.org\/10.1002\/pds.70050","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2024-02-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70050"}}